il-23 blockade with guselkumab potentially modifies psoriasis pathogenesis
Published 2 years ago • 1.1K plays • Length 6:14Download video MP4
Download video MP3
Similar videos
-
0:16
#shorts psoriasis pathogenesis: presenting the key role of keratinocytes
-
1:51
il-23s: psoriasis therapy overview
-
7:49
lxekizumab reduces key il-17 and il-23 pathway genes more rapidly than guselkumab | lam tsoi, phd
-
0:16
#shorts psoriasis pathogenesis: presenting the key role of keratinocytes
-
7:16
efficacy of il-23 inhibitors in plaque psoriasis
-
5:17
persistence and effectiveness of the il-12/23 pathway inhibitor ustekinumab
-
4:10
exploring the potential of guselkumab in psoriatic arthritis - medpage today
-
3:35
selecting from il-23s
-
2:34
il23 & il12/23 inhibitors: an overview
-
5:50
psoriasis and beyond: targeting the il-17 pathway
-
4:08
ixekizumab vs. guselkumab in plaque psoriasis, a. blauvelt et al
-
24:02
il-23 inhibitors and other emerging psoriasis treatments
-
3:24
wch23: il-17 vs il-23 blockers – why and when?
-
2:20
sglt2 inhibitors in primary care practice
-
5:14
efficacy and safety of guselkumab in patients with active psoriatic arthritis
-
5:11
use of il-23 inhibitors to treat plaque psoriasis
-
7:29
il-23: long-term data and safety data
-
1:36
history of psoriasis part two